{"id":"NCT02019472","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA速) Monotherapy in the Treatment of Active Rheumatoid Arthritis","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA速 Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-04","primaryCompletion":"2016-08-17","completion":"2016-08-17","firstPosted":"2013-12-24","resultsPosted":"2017-09-14","lastUpdate":"2017-10-26"},"enrollment":559,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab 40 mg","otherNames":["HUMIRA速"]},{"type":"BIOLOGICAL","name":"sirukumab 100 mg","otherNames":["CNTO 136"]},{"type":"BIOLOGICAL","name":"sirukumab 50 mg","otherNames":["CNTO 136"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1 (adalimumab 40 mg)","type":"EXPERIMENTAL"},{"label":"Group 2 (sirukumab 100 mg)","type":"EXPERIMENTAL"},{"label":"Group 3 (sirukumab 50 mg)","type":"EXPERIMENTAL"}],"summary":"The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic na誰ve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.","primaryOutcome":{"measure":"Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Adalimumab 40 mg","deltaMin":6.89,"sd":0.851},{"arm":"Sirukumab 50 mg","deltaMin":6.9,"sd":0.881},{"arm":"Sirukumab 100 mg","deltaMin":6.91,"sd":0.863}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"=0.013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":107,"countries":["United States","Bulgaria","Chile","Colombia","Germany","Hungary","Lithuania","Mexico","Moldova","Poland","Romania","Russia","Serbia","South Africa","Spain","Ukraine"]},"refs":{"pmids":["29483080"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":173},"commonTop":["Injection site erythema","Alanine aminotransferase increased","Rheumatoid arthritis","Aspartate aminotransferase increased","Nasopharyngitis"]}}